BeiGene Files 8-K: Other Events & Exhibits
Ticker: BEIGF · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-update
Related Tickers: BGNE
TL;DR
BeiGene filed an 8-K on 12/23/24 for other events and exhibits.
AI Summary
BeiGene, Ltd. filed an 8-K on December 23, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates BeiGene has submitted important corporate updates and financial information to the SEC, which could contain material disclosures for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational or financial risks.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Mourant Governance Services (Cayman) (company) — Agent for service of process
- December 23, 2024 (date) — Date of Report
FAQ
What specific 'Other Events' are being reported by BeiGene, Ltd. in this 8-K filing?
The provided text does not specify the details of the 'Other Events' reported by BeiGene, Ltd.
What is the filing date for this 8-K report?
The filing date for this 8-K report is December 23, 2024.
What is BeiGene, Ltd.'s principal executive office address?
BeiGene, Ltd.'s principal executive office is located at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is BeiGene, Ltd.'s Standard Industrial Classification (SIC) code?
BeiGene, Ltd.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-23 06:05:32
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
Filing Documents
- bgne-20241223.htm (8-K) — 33KB
- 0001651308-24-000171.txt ( ) — 153KB
- bgne-20241223.xsd (EX-101.SCH) — 2KB
- bgne-20241223_lab.xml (EX-101.LAB) — 21KB
- bgne-20241223_pre.xml (EX-101.PRE) — 12KB
- bgne-20241223_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 23, 2024, BeiGene, Ltd. (the "Company") announced that the Company's American Depository Shares ("ADSs") will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ONC" as of January 2, 2025. Currently, the Company's ADSs trade on the Nasdaq Global Select Market under the ticker symbol "BGNE".
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: December 23, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel